Editorial commentary: Every cardiologist should know diabetes by heart

[...]despite these promising improvements, DM remains a major cause of coronary artery disease, heart failure (HF), and stroke in all age groups and both sexes [2,4]. [...]the primary and secondary prevention of CVD is one of the primary goals of the management of patients with DM. Before the issuance of the Food and Drug Administration's guidance on the need for cardiovascular outcomes trials (CVOTs) for antidiabetic agents in 2008, we lacked dedicated large scale RCTs evaluating the long term cardiovascular outcomes of antidiabetic agents. [...]in the past decades, we have witnessed the rapid rise and subsequent fall of thiazolidinediones due to their side effects or cardiovascular safety profiles. Furthermore, a significant portion of patients with T2DM and ‘active’ CVD may encounter with their cardiovascular care providers more frequently than with their general practitioners or endocrinologists. [...]in order to achieve secondary and possibly primary cardiovascular prevention goals in this vulnerable patient population, cardiologists should actively participate in the discussion of healthy lifestyle choices and the decision making for antidiabetic agents in light of recent CVOTs.